S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.05%) $0.927
USD/NOK
(0.18%) $10.86
USD/GBP
(0.02%) $0.792
USD/RUB
(-0.16%) $92.43

Realtime updates for GENinCode plc [GENI.L]

Exchange: LSE Sector: Healthcare Industry: Diagnostics & Research
Last Updated28 Mar 2024 @ 12:29

10.00% £ 6.88

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 12:29):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally...

Stats
Today's Volume 708 105
Average Volume 258 242
Market Cap 11.06M
EPS £0 ( 2023-09-20 )
Next earnings date ( £0 ) 2024-06-04
Last Dividend £0 ( N/A )
Next Dividend £0 ( N/A )
P/E -1.150
ATR14 £0.219 (3.19%)

GENinCode plc Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GENinCode plc Financials

Annual 2022
Revenue: £1.43M
Gross Profit: £632 000 (44.20 %)
EPS: £-0.0580
Q2 2023
Revenue: £950 000
Gross Profit: £293 000 (30.84 %)
EPS: £-0.0365
Q1 2023
Revenue: £475 000
Gross Profit: £233 500 (49.16 %)
EPS: £-0.0183
Q4 2022
Revenue: £766 000
Gross Profit: £219 000 (28.59 %)
EPS: £-0.0337

Financial Reports:

No articles found.

GENinCode plc

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators